Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure
Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly. Arcturus is developing ARCT-810 for patients with OTCD, a rare genetic disorder in which the liver cannot properly remove toxic ammonia from the blood. ARCT-810 was generally safe and well tolerated in a Phase 2 study. BTIG … Read more